Share Twitter LinkedIn Facebook Email Nicholas Rohs MD @NickRohsMD Of Mount Sinai Discusses Frontline KEYTRUDA In Gastroesophageal Cancer: Patients In Immunotherapy Arm Had Significantly Lower Side Effects.
SGNTUC-024 Phase 1b/2 study: Tucatinib, trastuzumab, FOLFOX for HER2+ GI cancers Gastrointestinal 8 Mins Read